Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.

AIMS To determine the in vitro kinetics of morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) formation and the inhibition potential by methadone enantiomers and structurally related opioids. METHODS M3G and M6G formation kinetics from morphine were determined using microsomes from five human livers. Inhibition of glucuronide formation was investigated with eight inhibitors (100 microm) and the mechanism of inhibition determined for (R)- and (S)-methadone (70-500 microm) using three microsomal samples. RESULTS Glucuronide formation displayed single enzyme kinetics. The M3G Vmax (mean+/-SD) was 4.8-fold greater than M6G Vmax (555+/-110 vs. 115+/-19 nmol mg-1 protein h-1; P=0.006, mean of difference 439; 95% confidence interval 313, 565 nmol mg-1 protein h-1). Km values for M3G and M6G formation were not significantly different (1.12+/-0.37 vs. 1.11+/-0.31 mm; P=0.89, 0.02; -0.29, 0.32 mm). M3G and M6G formation was inhibited (P<0.01) with a significant increase in the M3G/M6G ratio (P<0.01) for all compounds tested. Detailed analysis with (R)- and (S)-methadone revealed noncompetitive inhibition with (R)-methadone Ki of 320+/-42 microm and 192+/-12 microm for M3G and M6G, respectively, and (S)-methadone Ki of 226+/-30 microm and 152+/-20 microm for M3G and M6G, respectively. Ki values for M3G inhibition were significantly greater than for M6G for (R)-methadone (P=0.017, 128; 55, 202 microm) and (S)-methadone (P=0.026, 75; 22, 128 microm). CONCLUSIONS Both methadone enantiomers noncompetitively inhibited the formation of morphine's primary metabolites, with greater inhibition of M6G formation compared with M3G. These findings indicate a mechanism for reduced morphine clearance in methadone-maintained patients and reduced relative formation of the opioid active M6G compared with M3G.

[1]  A. Somogyi,et al.  Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients. , 2004, British journal of clinical pharmacology.

[2]  A. Galetin,et al.  Isoform selectivity and kinetics of morphine 3- and 6-glucuronidation by human udp-glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[3]  D. Greenblatt,et al.  Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[4]  G. Tucker,et al.  A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. , 2003, British journal of clinical pharmacology.

[5]  T. Tephly,et al.  Inhibition and active sites of UDP-glucuronosyltransferases 2B7 and 1A1. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[6]  J. Miners,et al.  In vitro-in vivo correlations for drugs eliminated by glucuronidation: investigations with the model substrate zidovudine. , 2002, British journal of clinical pharmacology.

[7]  S. Joel,et al.  Limited phase I study of morphine-3-glucuronide. , 2001, Journal of pharmaceutical sciences.

[8]  Jason M. White,et al.  Methadone maintenance patients are cross-tolerant to the antinociceptive effects of morphine , 2001, Pain.

[9]  J B Houston,et al.  Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--towards a consensus. , 2001, British journal of clinical pharmacology.

[10]  F. Fulfaro,et al.  Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  D. Moody,et al.  Variables in human liver microsome preparation: impact on the kinetics of l-alpha-acetylmethadol (LAAM) n-demethylation and dextromethorphan O-demethylation. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[12]  S. Joel,et al.  Randomized placebo‐controlled trial of the activity of the morphine glucuronides , 2000 .

[13]  J. Miners,et al.  Nonspecific binding of drugs to human liver microsomes. , 2000, British journal of clinical pharmacology.

[14]  S. Wrighton,et al.  In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[15]  A. Somogyi,et al.  Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. , 1999, British journal of clinical pharmacology.

[16]  S. Hansen,et al.  Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long‐term administration?: Six case histories , 1998, Acta anaesthesiologica Scandinavica.

[17]  M. Green,et al.  Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. , 1998, Toxicological sciences : an official journal of the Society of Toxicology.

[18]  P. Jatlow,et al.  Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262). , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[19]  C. Jamis-Dow,et al.  Glucuronidation of 3′-Azido-3′-Deoxythymidine (Zidovudine) by Human Liver Microsomes: Relevance to Clinical Pharmacokinetic Interactions with Atovaquone, Fluconazole, Methadone, and Valproic Acid , 1998, Antimicrobial Agents and Chemotherapy.

[20]  M. Karlsson,et al.  Morphine-3-glucuronide has a minor effect on morphine antinociception. Pharmacodynamic modeling. , 1998, Journal of pharmaceutical sciences.

[21]  M. Green,et al.  Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[22]  J. Strong,et al.  The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[23]  P. Beaune,et al.  Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. , 1996, Chemical research in toxicology.

[24]  R. Moore,et al.  Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain. , 1996, Journal of pain and symptom management.

[25]  R. Shank,et al.  Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. , 1995, The Journal of pharmacology and experimental therapeutics.

[26]  T. Hedner,et al.  Morphine and morphine metabolite concentrations in cerebrospinal fluid and plasma in cancer pain patients after slow-release oral morphine administration , 1995, Pain.

[27]  Maree T. Smith,et al.  Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat , 1995, Pain.

[28]  A. Rane,et al.  Tricyclic antidepressants inhibit opioid receptor binding in human brain and hepatic morphine glucuronidation. , 1994, Pharmacology & toxicology.

[29]  S. Joel,et al.  The pharmacokinetics of morphine and morphine glucuronides in kidney failure , 1993, Clinical pharmacology and therapeutics.

[30]  S. Cordner,et al.  Methadone Toxicity Causing Death in Ten Subjects Starting on a Methadone Maintenance Program , 1992, The American journal of forensic medicine and pathology.

[31]  J. Morley,et al.  Differential inhibition of hepatic morphine UDP-glucuronosyltransferases by metal ions. , 1992, Biochemical pharmacology.

[32]  H. Thaler,et al.  The metabolite morphine‐6‐glucuronide contributes to the analgesia produced by morphine infusion in patients with pain and normal renal function , 1992, Clinical pharmacology and therapeutics.

[33]  T. Hedner,et al.  Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat , 1992, Pain.

[34]  A. Somogyi,et al.  High-performance liquid chromatographic determination of morphine and its 3- and 6-glucuronide metabolites: improvements to the method and application to stability studies. , 1991, Journal of chromatography.

[35]  M. Eichelbaum,et al.  Codeine O-demethylation: rat strain differences and the effects of inhibitors. , 1991, Biochemical pharmacology.

[36]  Maree T. Smith,et al.  Morphine-3-Glucuronide — A potent antagonist of morphine analgesia , 1990, Pain.

[37]  B. Burchell,et al.  The enantioselective glucuronidation of morphine in rats and humans. Evidence for the involvement of more than one UDP-glucuronosyltransferase isoenzyme. , 1989, Biochemical pharmacology.

[38]  A. Roche,et al.  Extrahepatic metabolism of morphine occurs in humans. , 1988, Clinical pharmacology and therapeutics.

[39]  J. Miners,et al.  In vitro evidence for the involvement of at least two forms of human liver UDP-glucuronosyltransferase in morphine 3-glucuronidation. , 1988, Biochemical pharmacology.

[40]  L. Hammar,et al.  Human liver morphine UDP‐glucuronyl transferase enantioselectivity and inhibition by opioid congeners and oxazepam , 1988, British journal of pharmacology.

[41]  G. Pasternak,et al.  Morphine-6-glucuronide, a potent mu agonist. , 1987, Life sciences.

[42]  J. Houston,et al.  Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. , 1987, Drug metabolism and disposition: the biological fate of chemicals.

[43]  L. Kager,et al.  Oral morphine in cancer patients: in vivo kinetics and in vitro hepatic glucuronidation. , 1985, British journal of clinical pharmacology.

[44]  V. Dole,et al.  A Medical Treatment for Diacetylmorphine (Heroin) Addiction , 1966 .

[45]  V. Dole,et al.  A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE. , 1965, JAMA.

[46]  M. M. Eisenberg.  Surgery of the Gall Bladder and Bile Ducts , 1965 .

[47]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. , 1964, The Journal of biological chemistry.

[48]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[49]  A. Rane,et al.  Morphine glucuronidation in human fetal and adult liver , 2004, European Journal of Clinical Pharmacology.

[50]  P. Fornaro,et al.  Pinazepam: A precursor of N-desmethyldiazepam , 2004, European Journal of Clinical Pharmacology.

[51]  M. Doverty.  Acute pain management in methadone maintenance treatment / by Mark Doverty. , 2001 .

[52]  S. Kaasa,et al.  Start of oral morphine to cancer patients: effective serum morphine concentrations and contribution from morphine-6-glucuronide to the analgesia produced by morphine , 2000, European Journal of Clinical Pharmacology.

[53]  T. Tephly,et al.  Human UGT2B7 catalyzes morphine glucuronidation. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[54]  L. Christrup,et al.  The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. , 1995, Life sciences.

[55]  S. Bartlett,et al.  The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex. , 1994, Life sciences.

[56]  B. Sproule,et al.  Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. , 1993, British journal of clinical pharmacology.

[57]  P. Selwyn,et al.  Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. , 1992, Journal of acquired immune deficiency syndromes.

[58]  Maree T. Smith,et al.  Morphine-3-glucuronide--a potent antagonist of morphine analgesia. , 1990 .